AOD-9604 vs Ipamorelin

Side-by-side comparison of AOD-9604, Ipamorelin — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute AOD-9604 hGH Fragment 176-191 (Anti-Obesity Drug 9604) Weight Loss Ipamorelin Ipamorelin (Selective GHRP) Growth Hormone
Basics
Molecular type hGH C-terminal FragmentGrowth Hormone Releasing Peptide (GHRP)
Amino acids 165
Molecular weight 1,815.1 Da711.9 Da
Half-life ~30 min~2 hours
Route(s) Subcutaneous, Oral (research)Subcutaneous, Intramuscular
Mechanism & Research
Primary mechanism AOD-9604 mimics the lipolytic (fat-breaking) action of the C-terminal fragment of growth hormone at the beta-3 adrenergic receptor in adipocytes. By activating beta-3 receptors, it promotes lipolysis (fat cell triglyceri… Ipamorelin activates growth hormone secretagogue receptors (GHSR-1a) in the pituitary, triggering pulsatile GH release. Unlike first-generation GHRPs (GHRP-6, GHRP-2), ipamorelin's selectivity for GHSR-1a is high enough …
Research status Research Compound Research Compound
Evidence summary AOD-9604 completed Phase 2b trials for obesity (METRO study) before development was discontinued. Despite clear mechanistic rationale and positive preclinical data, the Phase 2b trial did not demonstrate statistically si… Ipamorelin was among the first highly selective GHRPs to enter research. Phase 1 trials confirmed its clean hormonal profile. It remains a reference GHRP in comparative studies and is widely used as the GHRP component in…
Protocol & Dosing
Typical dose 300–500 mcg/day100–300 mcg per injection
Frequency Once daily2–3x daily (or 1x at bedtime)
Duration 8–12 weeks8–12 weeks on, 4 weeks off
Timing Pre-workout or morning on empty stomach (for metabolic effects)Fasted state or 2+ hours post-meal for maximum GH response; bedtime dosing utilises natural nocturnal GH pulse
Safety
Common side effects
  • Injection site redness
  • Mild flushing
  • Headache (transient)
  • Water retention (mild)
  • Tingling/numbness (extremities)
  • Headache (transient)
  • Injection site redness
Contraindications
  • Active cancer (theoretical, given GH receptor homology)
  • Pregnancy (no data)
  • Active malignancy
  • Uncontrolled diabetes
  • Pregnancy
Anti-doping Prohibited (WADA S2) Prohibited (WADA S2)
Deeper reading
Related peptides Semaglutide, Ipamorelin, Tesamorelin CJC-1295, GHRP-2, Sermorelin, Tesamorelin
Full profile Read full AOD-9604 profile → Read full Ipamorelin profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.